Evaxion says EVX-01 demonstrates 86% vaccine target precision in trial

Evaxion announces new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets. The data will be presented at the AACR Annual Meeting in San Diego, California, on April 22. “86% of the vaccine targets included in Evaxion’s personalized cancer vaccine EVX-01 trigger a tumor-specific immune response. This is a success rate much higher than what has been reported for other methods. The high number reflects a broad yet specific immune response, increasing the likelihood of strong anti-tumor effect and positive clinical outcomes,” the company stated. “We are delighted with the data demonstrating again the unique capabilities of AI-Immunology in identifying and selecting relevant vaccine targets. This is a further validation of the platform as an effective tool for developing potentially transformational treatments of cancer and other diseases,” says Bigitte Rono, CSO of Evaxion.